The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Breast cancer drug is a danger, disguised as a blessing

The Wild Wild West

Let’s say your company has developed a drug and received FDA approval. Congratulations! You’re on your way to untold riches!

Just one catch: Some busybody (like the California Environmental Protection Agency) publicly lists your drug as a potential carcinogen.

No! What rotten luck! Now the FDA will remove your product from the market, all your R&D money is down the drain, and you’ll be buried with lawsuits galore.

Just kidding! The FDA isn’t going to do a thing, you big silly head. And the lawsuits won’t materialize because the mainstream media will mostly ignore all that California EPA business. And while the risks will be publicly acknowledged, they’ll be put in context – something like: “The therapeutic benefits outweigh the risks.”

See? Just a few people will have to suffer from cancer so that the larger population can enjoy all the wonderful benefits. And most of the other potential side effects aren’t even life threatening!

But with the next drug you develop you really should be a little more careful and consult The Dow Acceptable Risk Calculator? before you put your product on the market. The calculator is free, easy to use, and will help you compute exactly how many people you can put at mortal risk and still make an obscene pile of cash.

Profit protection

No kidding. There really is a Dow Acceptable Risk Calculator?. You can find it at, where you’ll also find this quote: “Acceptable Risk? is a voluntary initiative of Dow to safely predict the precise point at which profitability is threatened by danger to the public.”

So if you’re producing a drug or a toxic pesticide or a dangerous baby formula, you can go to that website, answer a few questions about profit projections, potential human or environmental casualties, etc., and you’ll get a quick idea of your product’s acceptable risk.

Appalling? Absolutely. And that’s why it’s a devastating satire.

Neither the dowethics site nor the Acceptable Risk Calculator? have any connection to Dow Chemical Company. As for their connection to corporate reality in general – you’ll have to make that call yourself.

I came across when I was researching a tip sent to me by my colleague Melissa Hickle, Managing Editor of the HSI Members Alert. Melissa recently discovered that tamoxifen – a drug used to treat breast cancer – was identified as a carcinogen by the California EPA more than 10 YEARS ago!

And that information led me to one of the most astonishing quotes I’ve ever read.

Making a list, revising it twice

In several e-Alerts I’ve told you about the pros and cons of tamoxifen. On one hand, this synthetic hormone-like drug effectively prevents estrogen from binding to breast cancer cells. That’s why tamoxifen is more effective than chemotherapy in treating estrogen- driven breast cancer tumors – the most common type of breast cancer tumor in postmenopausal women.

Unfortunately the list of tamoxifen side effects reads like a list of menopausal symptoms: hot flashes, nausea, vomiting, weight gain, mood swings, depression, and loss of energy. Add deep-vein thrombosis and pulmonary embolism, and you’ve got a drug that should make any woman wonder: Is this an acceptable risk?

In 1995, a scientific panel reviewed studies that linked tamoxifen use with an increased risk of endometrial cancer, which occurs in the lining of the uterus. The panel voted to recommend that the California EPA identify tamoxifen as a carcinogen. Zeneca Pharmaceuticals (the maker of tamoxifen) fought back and managed to keep the drug off the list. But the EPA persevered and tamoxifen was finally added to the list, September 1, 1996.

Of course, tamoxifen is still on the market, sold under the brand name Nolvadex.

So let’s go to the bottom line: In addition to the endometrial cancer warning, all postmenopausal women with breast cancer should know that the National Cancer Institute advises patients that tamoxifen may actually INCREASE the chance of recurrence of breast cancer when the drug is taken for more than five years. But according to Breast Cancer Action, many doctors are hesitant to take their patients off tamoxifen when they reach the five-year mark.

Furthermore, the Breast Cancer Prevention Trial (reported in the Journal of the National Cancer Institute in 2000) found that when tamoxifen is taken to prevent breast cancer, benefits do not outweigh risks in women with a uterus over the age of 60 (and “many women 50-60”), and most women over the age of 70 (and “many women 60-70”) without a uterus.

Fearsome 400

That astonishing quote I referred to above comes from Catherine Caraway of the California EPA. In 1995, Ms. Caraway told Science News that more than 400 of the items on the EPA’s carcinogen list were drugs.

Can you imagine if folic acid or St. John’s wort were found to be carcinogenic? They would be banned within a week. But drugs? They ride free because (we’re assured) their risk is acceptable.

“Chemicals Known to the State to Cause Cancer or Reproductive Toxicity” State of California Environmental Protection Agency, 3/21/08,
“State Asks: Is Tamoxifen a Carcinogen? – California” Science News, 10/7/95,
“Tamoxifen on Trial: The Saga Continues” Nancy Evans, Breast Cancer Action, Newsletter #41, April/May 1997,
“Tamoxifen Used in Healthy Women: Risks and Benefits” National Breast Cancer Coalition,

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 


Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at